Kancera AB (publ) today announces that the top line results from the FRACTAL study are delayed. The company expects that results will be presented by the end of December 2023.
Read MoreIn connection with the release of the financial interim report for the second quarter of 2023, Kancera AB (publ) provides an operational update and announces that top line results from the ongoing FRACTAL study are expected to be presented...
Read MoreKancera AB (publ) today comments on the potential for its fractalkine blocking drug candidate KAND567 based on a newly published research publication that summarizes clinical research addressing the pathology driving role of fractalkine axis in cardiovascular disease. KAND567 is...
Read MoreKancera AB (publ) today reports that the first patient in the KANDOVA study, a combined phase Ib/IIa study in ovarian cancer, has been dosed with KAND567.
Read MoreKancera today reports that patient screening to the KANDOVA-study, a combined phase Ib/IIa study of the Fractalkine blocker KAND567 in ovarian cancer patients, has been started at the Karolinska University Hospital.
Read MoreKancera today reports that the company has submitted the regulatory application to conduct a First-In-Human study of its Fractalkine blocker KAND145.
Read MoreKancera AB (publ) today announces that it has submitted the regulatory application to the Swedish Medical Products Agency to conduct clinical studies of KAND567 in ovarian cancer and entered into an agreement with the Nordic Society of Gynaecological Oncology...
Read MoreKancera AB (publ) reports new preclinical results supporting the potential for KAN571, a ROR1 inhibitor, for treatment of mantle cell lymphoma (MCL), a subtype of B-cell malignancies. Preclinical studies of KAN571 in MCL cell lines show that KAN571 effectively...
Read MoreKancera AB (publ) reports new preclinical results supporting the potential for the company’s Fractalkine axis blocking candidate drugs to increase the efficacy of standard-of-care drug treatment of B-cell lymphomas, such as chronic lymphocytic leukemia (CLL).
Read MoreKancera AB (publ) is today reporting that patient recruitment to the ongoing phase IIa study of KAND567 in myocardial infarction patients is progressing well and 54 patients of the targeted 60 patients have been enrolled so far. The company...
Read More